ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-13 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 114.4 KB | ||
| 2025-08-13 18:00 |
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.7 KB | ||
| 2025-08-11 15:21 |
Franchissement de seuil
|
French | 111.2 KB | ||
| 2025-08-11 15:16 |
Franchissement de seuils
|
French | 117.2 KB | ||
| 2025-08-11 14:55 |
Franchissement de seuil
|
French | 96.7 KB | ||
| 2025-08-11 14:54 |
Franchissement de seuil
|
French | 82.9 KB | ||
| 2025-08-11 11:11 |
Franchissement de seuil
|
French | 99.3 KB | ||
| 2025-07-28 22:15 |
Abivax annonce la réalisation de son offre au public de 747,5 millions de dolla…
|
French | 161.2 KB | ||
| 2025-07-28 22:15 |
Abivax Announces Closing of $747.5 Million Public Offering
|
English | 15.0 KB | ||
| 2025-07-25 08:00 |
Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplément…
|
French | 159.5 KB | ||
| 2025-07-25 08:00 |
Abivax Announces Full Exercise of Underwriters Option to Purchase Additional AD…
|
English | 15.2 KB | ||
| 2025-07-24 14:40 |
Abivax annonce la reprise des négociations de ses actions ordinaires sur Eurone…
|
French | 116.2 KB | ||
| 2025-07-24 14:40 |
Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) …
|
French | 368.1 KB | ||
| 2025-07-24 07:30 |
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur …
|
French | 117.6 KB | ||
| 2025-07-24 07:30 |
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur …
|
French | 11.3 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
